Assessing patient-reported peripheral neuropathy: The reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire

Quality of Life Research

Volumn 22, Issue 10, 2013, Pages 2787-2799

  Smith, Ellen M Lavoie ^a   Barton, Debra L ^b   Qin, Rui ^b   Steen, Preston D ^c   Aaronson, Neil K ^d   Loprinzi, Charles L ^b  

^a UNIVERSITY OF MICHIGAN SCHOOL OF NURSING   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

^c MeritCare Roger Maris Cancer Center   (United States)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Chemotherapy; EORTC QLQ CIPN20; Peripheral neuropathy; Reliability; Validity

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; NEOPLASM; OUTCOME ASSESSMENT; PAIN; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; QUESTIONNAIRE; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; SOCIOECONOMICS; STANDARD;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN; PATIENT OUTCOME ASSESSMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS;

EID: 84892782989     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-013-0379-8     Document Type: Article

References (32)

1. Hausheer, F. H., Schilsky, R. L., Bain, S., Berghorn, E. J., & Lieberman, F. (2006). Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology, 33(1), 15-49.
2. Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012). Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Critical Reviews in Oncology-Hematology, 82(1), 51-77.
3. Stubblefield, M. D., Burstein, H. J., Burton, A. W., Custodio, C. M., Deng, G. E., Ho, M., et al. (2009). NCCN task force report: Management of neuropathy in cancer. Journal of the National Comprehensive Cancer Network, 7(Suppl 5), S1-S26.
4. Argyriou, A. A., Zolota, V., Kyriakopoulou, O., & Kalofonos, H. P. (2010). Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents. Journal of B.U.On, 15(3), 435-446.
5. Paice, J. A. (2009). Clinical challenges: Chemotherapy-induced peripheral neuropathy. Seminars in Oncology Nursing, 25(2 Suppl 1), S8-S19.
6. Loprinzi, C. L., Reeves, B. N., Dakhil, S. R., Sloan, J. A., Wolf, S. L., Burger, K. N., et al. (2011). Natural history of paclitaxel-associated acute pain syndrome: Prospective cohort study NCCTG N08C1. Journal of Clinical Oncology, 29(11), 1472-1478.
7. Visovsky, C., & Daly, B. J. (2004). Clinical evaluation and patterns of chemotherapy-induced peripheral neuropathy. Journal of the American Academy of Nurse Practitioners, 16(8), 353-359.
8. Wampler, M. A., Miaskowski, C., Hamel, K., Byl, N., Rugo, H., & Topp, L. S. (2006). The modified total neuropathy score: A clinically feasible and valid measure of taxane-induced peripheral neuropathy in women with breast cancer. Supportive Oncology, 4(8), W9-W16.
9. Bakitas, M. A. (2007). Background noise: The experience of chemotherapy-induced peripheral neuropathy. Nursing Research, 56(5), 323-331.
10. Smith, E. M. L., Bakitas, M. A., Homel, P., Piehl, M., Kingman, L., Fadul, C. E., et al. (2011). Preliminary assessment of a neuropathic pain treatment and referral algorithm for patients with cancer. Journal of Pain and Symptom Management, 42(6), 822-838.
11. Griffith, K., Merkies, I. S. J., Hill, E., & Cornblath, D. (2010). Measures of chemotherapy-induced peripheral neuropathy: A systematic review of psychometric properties. Journal of the Peripheral Nervous System, 15(4), 314-325.
12. Cavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Susani, E., Alberti, P., et al. (2010). Chemotherapy-Induced Peripheral Neurotoxicity assessment: A critical revision of the currently available tools. European Journal of Cancer, 46(3), 479-494.
13. Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., et al. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer, 41(8), 1135-1139.
14. Cleeland, C. S., & Ryan, K. M. (1994). Pain assessment: Global use of the brief pain inventory. Annals of the Academy of Medicine, Singapore, 23(2), 129.
15. Common Terminology Criteria for Adverse Events Version 4.02 (CTCAE). (2009). U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed 7 January, 2010.
16. Barton, D. L., Wos, E. J., Qin, R., Mattar, B. I., Green, N. B., Lanier, K. S., et al. (2011). A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Supportive care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer, 19(6), 833-841.
17. Reeves, B. N., Dakhil, S. R., Sloan, J. A., Wolf, S. L., Burger, K. N., Kamal, A., et al. (2012). Further data supporting that the paclitaxel-associated acute pain syndrome is associated with the development of peripheral neuropathy: NCCTG Trial N08C1. Cancer, 118(20), 5171-5178.
18. Ferketich, S. (1991). Focus on psychometrics: Aspects of item analysis. Research in Nursing & Health, 14(2), 165-168.
19. Boehmer, S., & Luszczynska, A. (2006). Two kinds of items in quality of life instruments: 'Indicator and causal variables' in the EORTC qlq-c30. Quality of Life Research, 15(1), 131-141.
20. Fayers, P. M. (2004). Quality-of-life measurement in clinical trials-the impact of causal variables. Journal of Biopharmaceutical Statistics, 14(1), 155-176.
21. Pett, M. A., Lackey, N. R., & Sullivan, J. L. (2003). Making sense of factor analysis: The use of factor analysis for instrument development in health care research. Thousand Oaks: Sage Publications.
22. Barrett, P. P. (2007). Structural equation modeling: Adjudging model fit. Personality and Individual Differences, 42(5), 815-824.
23. Flora, D. D. B. (2004). An empirical evaluation of alternative methods of estimation for confirmatory factor analysis with ordinal data. Psychological Methods, 9(4), 466-491.
24. Hayduk, L. L. (2007). Testing! testing! one, two, three-Testing the theory in structural equation models! Personality and Individual Differences, 42(5), 841-850.
25. Beauducel, A. A. (2005). Simulation study on fit indexes in CFA based on data with slightly distorted simple structure. Structural Equation Modeling, 12(1), 41-75.
26. Fan, X. X. (2005). Sensitivity of fit indexes to misspecified structural or measurement model components: Rationale of twoindex strategy revisited. Structural Equation Modeling, 12(3), 343-367.
27. Basch, E., Jia, X., Heller, G., Barz, A., Sit, L., Fruscione, M., et al. (2009). Adverse symptom event reporting by patients vs clinicians: Relationships With clinical outcomes. Journal of the National Cancer Institute, 101(23), 1624-1632.
28. Cohen, J. (1988). Statistical power analysis for the behavioral sciences. Hillsdale, New Jersey: Lawrence Earlbaum and Associate.
29. Clayton, M. F., & Pett, M. A. (2011). Modeling relationships in clinical research using path analysis Part II: Evaluating the model. Journal for Specialists in Pediatric Nursing: JSPN, 16(1), 75-79.
30. Hu, L. L. (1999). Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Structural Equation Modeling, 6(1), 1-55.
31. Zheng, Z. E. (2010). Research note-toward a causal interpretation from observational data: A new bayesian networks method for structural models with latent variables. Information Systems Research, 21(2), 365-391.
32. Spirtes, P., Glymour, C., Scheines, R., & Tillman, R. (2010). Automated search for causal relations: Theory and practice. In R. Dechter, H. Geffner, & J. Y. Halpern (Eds.), Heuristics, probability, and causality: A tribute to judea pearl (pp. 467-506). London, UK: College Publications.